Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model.

Tomoki FukuyamaSarah EhlingJenny WilzopolskiWolfgang Bäumer

Published in: BMC pharmacology & toxicology (2018)

These data indicate a similar beneficial potential of topical high dose PR022 HOCl (0.1%) in gel and tofacitinib, in a translational murine model of atopic dermatitis.

Keyphrases

atopic dermatitis
high dose
rheumatoid arthritis
wound healing
ulcerative colitis
low dose
electronic health record
stem cell transplantation
big data
fluorescent probe
human health
artificial intelligence
clinical evaluation